Background: Pioglitazone (PIO) is a new class of anti-diabetic agent with an anti-inflammatory effect. In the experimental studies, pretreatment with PIO before ischemia/reperfusion reduced ischemia-reperfusion injury and myocardial infarct size. However, the clinical efficacy of this therapy in patients with acute myocardial infarction (AMI) remains unknown.
eperfusion therapy by using percutaneous coronary intervention (PCI) reduces infarct size, improves left ventricular function and leads to better clinical outcomes in patients with acute myocardial infarction (AMI). 1 However, reperfusion therapy can also elicit adverse reactions that might limit its beneficial action, leading to irreversible cardiac damage. 2, 3 Although many non-clinical and clinical studies have been conducted to find effective adjunctive therapy for the reduction or prevention of these adverse reactions, few agents are available in the clinical settings. [4] [5] [6] Thiazolidinediones (TZDs), like pioglitazone (PIO) or rosiglitazone, are a novel class of oral antidiabetic agents currently used to treat Type 2 diabetes mellitus. These drugs increase insulin sensitivity and have favorable effects on blood glucose and lipid profiles. 7, 8 Besides these beneficial effects, TZDs have pleiotropic and anti-inflammatory properties. 9- 12 Recently, a number of experimental studies have reported that treatment with PIO before myocardial ischemiareperfusion has some protective effects against ischemiareperfusion injury by attenuating the inflammatory response, and resulted in the reduction of myocardial infarct size in a rat model of AMI. 13-15 Therefore, it is expected that pretreatment with PIO might lead to the prevention of reperfusion injury and preservation of cardiac function in the clinical setting of AMI. However, there have been no clinical studies investigating the efficacy of PIO in patients with AMI.
In the present study, we investigated the clinical impact of pretreatment with PIO in diabetic patients with AMI who underwent PCI.
Methods

Study Population
From April 2003 to July 2008, a total of 972 patients with AMI were admitted to our facility. Of these, we studied diabetic patients with AMI who were successfully treated with PCI using stents within 24 h of the onset. The diagnosis of AMI was based on chest pain lasting ≥30 min, ST-segment elevation ≥2 mm in at least 2 contiguous electrocardiography leads and a greater than three-fold increase in serum creatine kinase (CK) level. The following patients were excluded from the present study: patients with cardiogenic shock, severe Pioglitazone for Acute Myocardial Infarction congestive heart failure at the time of enrollment (class III or IV according to NYHA), left main stenosis more than 50% in diameter, and serum creatinine over 2.0 mg/dl. In the present study, a diabetic patient was defined as one previously diagnosed with diabetes mellitus and treated by diet therapy, antidiabetic drugs or insulin therapy. In all, 319 diabetic patients with AMI were examined in the present study. Of these, 26 patients had already been treated with PIO before the onset of AMI. In the present study, the study population was divided into the following 2 groups: PIO group [pretreatment with PIO (+); n=26] and non-PIO group [pretreatment with PIO (-); n=293]. Informed consent was obtained from every patient before the procedures. 
PCI Procedures
Emergent coronary angiography followed by PCI was performed to restore Thrombolysis In Myocardial Infarction (TIMI) III grade flow in the infarct related artery by using a stent. All procedural decisions including device selection and adjunctive pharmacotherapy were made at the discretion of the individual PCI operator. Intravenous unfractionated heparin (5,000 IU) and intracoronary nitroglycerin (0.5 mg) were administered before PCI. After stent implantation, angiographic optimization was performed by high-pressure dilatation to achieve an acceptable angiographic result. Intravascular ultrasound was used according to the operator's decision. Procedural success was defined as a residual stenosis of <20% without major complications (ie, AMI, need for emergent coronary artery bypass surgery or repeat PCI, or death). Following PCI, left ventrciulography (LVG) was performed to evaluate left ventricular function. All patients received 324 mg/day of aspirin for at least 24 h before the procedure. Dual anti-platelet therapy (aspirin 200 mg and ticlopidine 200 mg) was prescribed to all patients treated with bare metal stent (BMS) for 2 weeks. At 6 months, we performed a follow-up coronary angiography and LVG. Slow flow was defined as TIMI grade II flow and no reflow was defined as TIMI grade 0 or I flow in the distal infarct related artery despite the absence of an occlusion or dissection at the treatment site.
Assessment of Infarct Size and Reperfusion Quali
Blood samples were obtained on admission and at 3-h intervals. CK and CK-MB levels were measured at 3-h intervals until CK and CK-MB levels peaked, and those values were used as the enzymatic marker of infarct size. Left ventricular end-diastolic, end-systolic volume indexes (LVEDVI, LVESVI, respectively) and ejection fraction (LVEF) were measured by the area-length method in LVG. Reperfusion quality (eg, coronary microcirculation) was assessed by ST-segment resolution and myocardial blush grade. Complete ST resolution was defined as a reduction of at least 50% in ST-segment elevation on electrocardiographies obtained 1 h after reperfusion compared with the initial value. 16 If the ST-segments in the leads corresponding to the infarct-related lesion showed additional elevation (>2 mm) shortly after reperfusion, and this elevation persisted for at least 1 h after reperfusion, we defined it as ST-segment re-elevation. 17 The myocardial blush score was determined by 2 observers, who were unaware of the clinical and angiographic findings, using a previously reported grading scale. 18 Plasma brain natriuretic peptide (BNP) was measured at 1 week and 6 months after PCI.
Clinical Follow up
Follow-up information on the study population was obtained during a patient visit at the outpatient clinic or from a review of the medical records. Follow up was completed for all patients (follow-up rate 100%). The primary endpoint was defined as the occurrence of any major adverse cardiovascular events [MACE, defined as death due to all-cause death, non-fatal myocardial infarction and target lesion revascularization (TLR)]. Myocardial infarction was defined as evidence of 2 or more of the following: (1) typical chest pain >20 min not relieved by nitroglycerin; (2) serial electrocardiogram recordings show- Poor, n (%) 23 (8) 3 (12) Fair, n (%) 108 ( ing changes from baseline in ST-T and/or Q-waves in 2 or more contiguous leads; and (3) total serum CK greater than 2x the upper limit of normal. TLR was defined as clinically driven repeat revascularization (either repeated PCI or coronary artery bypass surgery) of the initially treated target lesion, including stented segments and peri-stent segments 5 mm from both the proximal and distal stent edges. The clinical and angiographic characteristics and the incidence of MACE were compared between the 2 groups. Continuous data are expressed as mean ± SD. A comparison between the 2 groups was performed by using the χ2 test (or the Fisher exact test) for categorical data. Analysis of variance (ANOVA) was performed for continuous data. Because hyperglycemia on admission potentially exacerbates myocardial perfusion in patients with AMI, the difference in plasma glucose level on admission between the 2 groups was controlled in the current study. The incidence of a blush score ≥2 and complete ST resolution Myocardial Blush score, and a complete ST resolution were analyzed using an analysis of covariance model (ANCOVA), with treatment (PIO or non-PIO) as a fixed effect and glucose level on admission as a covariate. A P value of <0.05 was considered to be statistically significant. All analyses were performed using SPSS 15.0 for Windows (SPSS, Inc, Chicago, IL, USA).
Results
Baseline Characteristics
Baseline characteristics are summarized in Table 1 . There were no significant differences in the baseline characteristics between the 2 groups. The prevalence of pre infarction angina was non-significantly higher in the PIO group than in the non-PIO group, and the difference was not statistically significant (P=0.08).
In the glycemic profile, the plasma blood glucose level on admission was significantly lower in the PIO group than in the non-PIO group. Although HbA1c was also lower in the PIO group, this was not statistically significant (P=0.09). Lipid profile and level of inflammation markers on admission were similar in the 2 groups. The use of Voglibose and insulin was significantly higher in the non-PIO group than in the PIO group. Table 2 shows the angiographic and procedural characteristics of the 2 groups. All patients underwent BMS implantation following coronary thrombectomy. Pre and final TIMI flow grades, percent diameter stenosis, the number of diseased vessel and collateral grade were similar between the 2 groups. None of the patients in the PIO group exhibited additional ST re-elevation, slow flow or no-reflow phenomenon, and distal embolism. In addition, the percentage of patients with a blush score ≥2 and complete ST resolution was significantly higher in the PIO group than in the non-PIO group (Figure) . Importantly, even after adjustment for this difference, a higher incidence of blush score ≥2 and complete ST resolution was still observed in the PIO group compared with that in the non-PIO group (blush score ≥2: 75% vs. 41%, P=0.04; complete ST resolution: 69% vs. 43%, P=0.04). Reperfusion arrhythmia was not induced during the PCI procedure. Table 3 shows the results of LVG and BNP levels. LVEF, LVEDVI and LVESVI immediately after PCI were similar in the 2 groups, and the BNP level at 1 week after PCI in the PIO group was also similar to that in the non-PIO group. At 6 months after PCI, the LVEF and BNP levels showed a favorable improvement compared with those in the non-PIO group, although these were not statistically significant (P= 0.10 and P=0.06, respectively). There was a trend toward a lower peak of CK and CK-MB levels in the PIO group com- In the non-PIO group, PIO was initiated in 30 patients (10%) after PCI. During a 6-month follow-up period, the incidence of restenosis and TLR was significantly lower in the PIO group than in the non-PIO group, whereas there were no significant differences in the incidence of death, non-fatal myocardial infarction and heart failure ( Table 4) . The incidence of MACE was also significantly lower in the PIO group than in the non-PIO group mainly due to TLR.
Angiographical and Procedural Characteristics
Leftventriculography Data and the 6-Month Outcomes
Discussion
The present study suggests that pretreatment with PIO reduced ischemia/reperfusion injury in diabetic patients with AMI. In addition, this pretreatment resulted in favorable changes in myocardial infarct size and cardiac function, although these were not statistically significant. Thus, our results indicate a therapeutic potential for PIO with the reduction of reperfusion injury in diabetic patients with AMI.
Cardioprotective Efficacy of PIO in Patients With AMI
The TZDs, which are peroxisome proliferation-activated receptor-γ agonists, have an insulin-sensitizing effect and various pleiotropic and anti-inflammatory properties. 7-12 In some recent experimental studies using a rat model, treatment with PIO before myocardial ischemia-reperfusion reduced myocardial infarct size by attenuating reperfusion injury. 13,15, 19 Although some clinical studies have examined the efficacy of PIO initiated after reperfusion therapy in patients with AMI, they failed to prove a beneficial effect on myocardial infarct size and reperfusion injury. 20, 21 Because PIO was administered before reperfusion in most of the experimental studies, we investigated patients who had already been treated with PIO before the onset of AMI. The present study showed that pretreatment of patients with PIO results in better myocardial perfusion than those not pretreated with PIO. This is the first study to demonstrate the efficacy of PIO for the reduction of reperfusion injury in the clinical setting of AMI.
Prevention of Reperfusion Injury by PIO
Immediate reopening of acutely occluded coronary arteries by primary PCI is the treatment of choice to salvage ischemic myocardium in the setting of AMI. However, the sudden reinitiation of blood flow can lead to further endothelial and myocardial damage, and it is reported that this phenomenon is partly due to an inflammatory response and apoptosis. 3,22-24 Recent experimental studies have shown that PIO attenuates myocardial/ischemia reperfusion injury by the reduction of inflammatory reactions such as monocyte chemoattractant protein-1, tumor necrosis factor-α and intercellular adhesion molecule-1 following reperfusion. Moreover, it exerted antiapoptic effects in cardiomyocytes by the activation of Akt, 13-15 and reduced ischemia-reperfusion arrhythmias and myocardial infarct size via the opening of mitochondrial adenosine triphosphate sensitive potassium channels. 13,15, 25 In the present study, pretreatment with PIO resulted in a higher percentage of the blush score ≥2 and a complete ST resolution, and reperfusion arrhythmias were unlikely to be induced in the PIO group. In addition, these results were still observed even after adjusted for the difference in plasma glucose level on admission between the 2 groups. Our findings indicate the clinical impact of pretreatment with PIO for the reduction of reperfusion injury in patients with AMI, and the above noted mechanism of PIO itself might be related to these favorable efficacies. As shown in our results, the PIO group had a lower glucose level on admission. It has been suggested that the surge of stress hormones such as cate- The usage of higher doses of PIO in larger study populations might enable us to detect significant changes in infarct size and cardiac function. PIO suppresses in-stent neointimal proliferation after BMS implantation and reduces the incidence of TLR after PCI 29, 30 because of the anti-inflammatory effect and an inhibitory effect on smooth muscle migration and proliferation. 31, 32 In the current study, the use of PIO after the onset of AMI was significantly lower in the non-PIO group than in the PIO group (10% vs. 100%, P<0.001). Those pleiotropic effects of PIO and the difference in use of PIO seem to be related to the lower rate of restenosis and TLR after PCI in the PIO group.
Several publications have suggested possible unfavorable effects of TZDs that increase the incidence of myocardial infarction and heart failure. 33-35 Meta-analyses by Nissen and Wolski demonstrated that rosiglitazone treatment potentially increased the incidence of myocardial infarction and was associated with a higher risk of death from cardiovascular causes that had borderline significance. 33, 34 Although it has been reported that there is an increased risk of heart failure caused by PIO treatment, observational studies suggest no increased risk of death or myocardial infarction with PIO treatment compared with other oral hypoglycemic agents. [36] [37] [38] Also, in the present study, despite high-risk clinical profiles, there were no events of myocardial infarction, heart failure and death in the PIO group. Given that the small study population of this study seems to be underpowered to detect the risk of PIO in diabetic patients with AMI, a larger study will be needed to examine the safety of PIO in these patients.
Study Limitations
This was a non-randomized, single-center retrospective study performed on a relatively low number of patients. This might have introduced a significant bias in patient and therapeutic selection.
The combination of PIO and statin has stronger antiinflammatory effects compared with PIO alone. 39 This combination therapy might have produced more favorable changes in myocardial reperfusion. In the present study, 65% of patients in the PIO group were treated with statin, and the prevalence of complete ST resolution and blush score of more than 2 in patients treated with both PIO and statin was similar to that in patients treated with PIO alone.
Conclusion
In the present study, pretreatment with PIO seems to result in better myocardial perfusion with less reperfusion injury in diabetic patients with AMI. Our results suggest that PIO is potentially cardioprotective in diabetic patients with AMI. A larger study is warranted to confirm these interesting results.
